Floatz logo

Belimumab

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

University Hospital Tuebingenmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB
Prednisone
AstraZeneca
Phase 3BBB

View all 50 →

Same molecule, other indications

Belimumab is also rated in:

Sjogren syndromeActive
B
Indicative · Phase 4
63 / 100
View asset →
childhood acute lymphoblastic leukemiaActive
B
Indicative · Phase 4
61 / 100
View asset →
multiple sclerosisActive
CCC
Indicative · Phase 2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →